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Abstract
Background: Despite the advent of highly active anti-retroviral therapy (HAART), HIV-associated neurocognitive disorders
continue to be a significant problem. In efforts to understand and alleviate neurocognitive deficits associated with HIV, we
used an accelerated simian immunodeficiency virus (SIV) macaque model of NeuroAIDS to test whether minocycline is
neuroprotective against lentiviral-induced neuronal injury.
Methodology/Principal Findings: Eleven rhesus macaques were infected with SIV, depleted of CD8+ lymphocytes, and
studied until eight weeks post inoculation (wpi). Seven animals received daily minocycline orally beginning at 4 wpi.
Neuronal integrity was monitored in vivo by proton magnetic resonance spectroscopy and post-mortem by
immunohistochemistry for synaptophysin (SYN), microtubule-associated protein 2 (MAP2), and neuronal counts. Astrogliosis
and microglial activation were quantified by measuring glial fibrillary acidic protein (GFAP) and ionized calcium binding
adaptor molecule 1 (IBA-1), respectively. SIV infection followed by CD8+ cell depletion induced a progressive decline in
neuronal integrity evidenced by declining N-acetylaspartate/creatine (NAA/Cr), which was arrested with minocycline
treatment. The recovery of this ratio was due to increases in NAA, indicating neuronal recovery, and decreases in Cr, likely
reflecting downregulation of glial cell activation. SYN, MAP2, and neuronal counts were found to be higher in minocycline-
treated animals compared to untreated animals while GFAP and IBA-1 expression were decreased compared to controls.
CSF and plasma viral loads were lower in MN-treated animals.
Conclusions/Significance: In conclusion, oral minocycline alleviates neuronal damage induced by the AIDS virus.
Citation: Ratai E-M, Bombardier JP, Joo C-G, Annamalai L, Burdo TH, et al. (2010) Proton Magnetic Resonance Spectroscopy Reveals Neuroprotection by Oral
Minocycline in a Nonhuman Primate Model of Accelerated NeuroAIDS. PLoS ONE 5(5): e10523. doi:10.1371/journal.pone.0010523
Editor: Howard E. Gendelman, University of Nebraska, United States of America
Received January 6, 2010; Accepted April 13, 2010; Published May 7, 2010
Copyright:  2010 Ratai et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits
unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Funding: This work was supported by NIH grants R21NS059331 (EMR), R01NS050041 (RGG), R01NS040237 (KW), R01NS37654 (KW), R01MH62962 (EM), MH59754
(EM), MH62512 (EM), and RR00168 (NEPRC Base Grant). Depleting anti-CD8 (human recombinant, cM-807) used in these studies were provided by the NIH
Nonhuman Primate Reagent Resource (R24 RR016001, N01 AI040101). The Massachusetts General Hospital A.A. Martinos Center for Biomedical Imaging is also
supported by the National Center for Research Resources grant number P41RR14075 and the Mental Illness and Neuroscience Discovery (MIND) Institute. The
funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.
Competing Interests: The authors have declared that no competing interests exist.
* E-mail: ratai@nmr.mgh.harvard.edu
¤a Current address: Brandeis University, Waltham, Massachusetts, United States of America
¤b Current address: Oregon National Primate Research Center, Beaverton, Oregon, United States of America
Introduction
Early in the AIDS epidemic, severe neurological disorders
including dementia were found to be caused by HIV [1,2]. The
use of antiretroviral drugs has greatly reduced the incidence of
dementia, but neurocognitive complications of the virus, known as
HIV-associated neurocognitive disorders (HAND), continue to be
an important problem [3,4,5]. The general consensus of
neuropathogenesis is that HIV enters the CNS primarily through
the trafficking of virally infected/activated monocytes [6,7]. This
influx of infected/activated monocytes induces astrocytosis and
microgliois. The production of neurotoxic substances by activated
glia and infected macrophages as well as the presence of
viral products likely cause neuronal cell injury and death [8,9],
which contribute to the neurologic impairment in HAND.
Furthermore, the central nervous system can act as a reservoir
for HIV due to the limited penetration of antiretroviral agents into
the CNS [10].
PLoS ONE | www.plosone.org 1 May 2010 | Volume 5 | Issue 5 | e10523The persistence of cumulative neurological disease despite
antiretroviral therapy has led to a search for adjunctive therapies.
Minocycline, an antibiotic with demonstrated neuroprotective
properties, is being tested clinically in neuroAIDS (Clinial trial
NCT00361257). The benefits of using minocycline are multifac-
eted including effects against apoptotic cell death, inflammation,
microglial activation [11–14] and viral production [15,16].
However, the benefits of MN and its mechanism of action in
HAND remain unclear.
In this study, we conducted serial neuroimaging using in vivo
1H
magnetic resonance spectroscopy (
1H MRS) to assess the effects of
minocycline on the brain injury produced by lentiviral infection in
an accelerated macaque model of neuroAIDS. The rapidly
progressing simian immunodeficiency virus (SIV)-infected ma-
caque model uses a monoclonal antibody to persistently deplete
the animal of CD8+ lymphocytes [17,18] resulting in AIDS
generally within 3 months with consistent development of
astrogliosis, microgliosis, and neuronal injury [19]. Moreover,
the alterations in brain metabolite concentrations in this model
measured by in vivo
1H MRS, particularly N-acetylaspartate/
Creatine (NAA/Cr), are very similar to those found in people with
HAND. We longitudinally examined a group of rhesus macaques
infected with SIV and CD8+ cell depleted (n=11), a subset of
which received minocycline (n=7). We demonstrate an arrest of
declining NAA/Cr, indicative of restoration of neuronal metab-
olism, and decreases in astrogliosis, microglial activation, and
neuronal loss with minocycline treatment in SIV-infected
macaques.
Results
CD8 T lymphocyte Depletion and Cohort Designation
Animals treated with anti-CD8 depleting antibody were either
persistently depleted before reemergence of peripheral CD8 cells
(.28 days, n=8) or short-term depleted (,21 days, n=3,
recovered to 31,000/mL or 6.5% of WBC). Four MN-treated
animals were persistently depleted and three were short-term
depleted. Four untreated infected animals were persistently
depleted. All analyses were performed on these 3 groups of
animals: 1) infected, untreated, persistently CD8-depleted animals,
2) infected, MN-treated, persistently CD8-depleted animals, and 3)
infected, MN-treated, short-term CD8-depleted, infected animals.
Plasma and CSF Viral Loads
After SIV inoculation, the amount of virus in the peripheral
blood plasma increased rapidly in all 3 cohorts, attaining levels
greater than 10
7 eq/mL by 12 days post inoculation (dpi)
(p,0.001, Figure 1A). The plasma viral load in untreated animals
continued to increase to a maximum of 4.9610
8 eq./mL, which
was detected at both 41 dpi and 61 dpi. Increases in viral loads
were statistically significant between 20 and 41 dpi in untreated
animals (Holm’s t-test p,0.001) while no further increase in
plasma viral loads was observed in the MN-treated animals after 8
dpi. The animals whose CD8 T lymphocytes rebounded before 21
dpi and that received MN treatment had 1.5–2 orders of
magnitude lower viral loads throughout the course of infection.
The three cohorts had different plasma viral loads at 55 dpi
(p=0.003). Both minocycline cohorts had lower viral loads
compared to untreated animals at 55 dpi (short-term CD8-
depleted animals, p=0.0017, and persistently CD8-depleted
animals, p=0.0034).
Figure 1B illustrates the CSF viral loads from the three cohorts
over the duration of SIV infection. In all cohorts, peak levels of
CSF virus were observed between 12 and 21 dpi. Significant
declines from peak levels were only observed in the MN-treated
animals. Persistently CD8-depleted, MN-treated animals showed a
significant decline in CSF viral load between 21 dpi and the final
scan (p=0.002). Short-term CD8-depleted, MN-treated animals
also had significant decreases from time of peak viral load and
subsequent time points (21 dpi vs. 27 dpi p=0.003, 21 dpi vs. 41
dpi p,0.001 and 21 dpi vs. 55 dpi p,0.001).
Magnetic Resonance Spectroscopy
In vivo
1H MR spectra were acquired from the parietal cortex
(PC), frontal cortex (FC), basal ganglia (BG) and white matter
semiovale (WM). Figure 2 shows representative spectra acquired
from an untreated animal prior to infection (Figure 2A, left) and at
Figure 1. Viral loads in plasma and CSF. Mean viral load in
untreated animals (solid squares), minocycline (MN)-treated persistently
CD8-depleted animals (open circles) and MN-treated short-term CD8-
depleted animals (open triangles) in plasma (A) and CSF (B) over the
time course of SIV infection until 8 weeks post inoculation. Error bars
represent standard error of the mean. The arrows represent the time
point when minocycline (MN) treatment was initiated.
doi:10.1371/journal.pone.0010523.g001
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minocycline treated, persistently CD8-depleted animal prior to
infection (Figure 2B, left) and at 8 wpi (Figure 2B, right).
1HM R
spectra acquired with short echo time (TE=30 ms) are charac-
terized by resonances primarily arising from N-acetylaspartate and
N-acetylaspartylglutamate (collectively referred to as NAA),
choline-containing compounds (referred to as Cho), myo-Inositol
(MI), creatine-containing compounds (referred to as Cr) and the
glutamate and glutamine concentrations (so-called Glx). Consis-
tent with previous studies [19] the neuronal metabolism marker
NAA is decreased while MI and Cho are increased in the
untreated, CD8-depleted animals at 8 wpi compared to preinfec-
tion spectrum (Figure 2A). In contrast, the 8 wpi spectrum from
the MN-treated animal is nearly the same as the preinfection
Figure 2. Comparison of
1H MR spectra of untreated and minocycline treated macaques. (A)
1H MR spectra from the white matter of a
representative untreated macaque before infection and at 8 wpi. Spectra are scaled to the creatine (Cr) resonance. It can be seen from the spectra
that NAA is decreased and Cho is increased at 8 wpi compared to baseline levels. (B)
1H MR spectra from the white matter of a representative
minocycline treated (persistently CD8-depleted) macaque before infection and at 8 wpi. Again, the spectra are scaled to the creatine resonance. It is
clear that NAA/Cr has not decreased as much and also that Cho/Cr has not increased at 8 wpi.
doi:10.1371/journal.pone.0010523.g002
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CD8-depleted controls exhibited no difference in pre- and post-
depletion spectra (data not shown) [20]. N-acetylaspartate is a
marker for neuronal integrity [21,22] and creatine is a biomarker
of energy metabolism likely localized to glial activation [23,24].
Choline increases are indicative of membrane turnover due to glial
activation and myo-Inositol elevation is considered to reflect
increased glial cell activity [25].
Changes in NAA/Cr ratio. The mean percent changes in
the levels of NAA/Cr as a measure of neuronal metabolism with
respect to time after SIV infection in each brain region are
graphically displayed in Figure 3. Analysis of the MR spectra from
all eleven animals before treatment revealed decreases in NAA/Cr
at 2 wpi in the BG (p=0.009) and WM (p=0.007), and at 4 wpi in
the PC (p=0.002), FC (p=0.002) and WM (p,0.001). The four
SIV-infected untreated animals (solid squares) had a 16% decrease
in NAA/Cr in the PC over the 8 weeks following inoculation
(p,0.001), as well as declines of 19% in the FC (p,0.001), 13% in
the BG (p=0.004) and 17% in the WM (p,0.001). The declines
in NAA/Cr were significant at both 6 and 8 wpi when compared
to pre-infection scans.
For the four SIV-infected, persistently CD8-depleted MN-
treated animals (open circles), four weeks of MN treatment starting
at 4 wpi resulted in a stabilization of NAA/Cr levels in all regions
with partial recovery to values that were not significantly different
from baseline. Treatment with MN resulted in progressive increase
in NAA/Cr levels after treatment initiation in all brain regions in
the three SIV-infected, short-term CD8-depleted, MN treated
animals (solid triangles) (Figure 3).
The SIV-infected untreated animals exhibited the lowest levels
of NAA/Cr at the end of the study (8 wpi) in all brain regions
examined (Figure 4). NAA/Cr was significantly higher in all brain
regions in the MN-treated, short-term CD8-depleted animals
when compared to the SIV-infected animals that did not receive
MN animals. NAA/Cr was also significantly higher in the FC, BG
and WM of the SIV-infected MN-treated, persistently CD8-
depleted animals compared to untreated animals. Although NAA/
Cr tended to be higher in those MN treated animals that
Figure 3. Recovery of neuronal marker NAA/Cr with minocycline treatment in SIV infection. NAA/Cr over the course of SIV infection in
untreated animals (solid squares), minocycline (MN)-treated persistently CD8-depleted animals (open circles) and MN-treated short-term CD8-
depleted animals (solid triangles). Mean NAA/Cr measured in the parietal cortex (A), frontal cortex (B), basal ganglia (C) and white matter semiovale
(D) are plotted over time. Error bars represent standard error of the mean. The arrows represent the time point when minocycline (MN) treatment
was initiated.
doi:10.1371/journal.pone.0010523.g003
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between the two MN-treated cohorts did not reach significance.
Changes in NAA and Creatine concentrations. The
differences detected in the NAA/Cr ratio in various brain
regions may be due to changes in either or both metabolites. In
an attempt to identify whether changes in NAA and/or Cr are
responsible for the changes observed in the ratio, NAA and Cr
concentrations were estimated using tissue water as the internal
standard. Due to the fact that there are over four orders of
magnitude differences between the concentrations of the
metabolites and water concentrations, the values have a much
higher variance compared to the metabolite-metabolite ratios.
Naturally, this makes obtaining statistical significance more
difficult than for comparisons involving metabolite-metabolite
ratios.
The mean NAA concentrations in untreated SIV-infected
animals declined relative to baseline measurements in each brain
region analyzed, but the differences were statistically significant
only in the WM (PC -4% p=0.68, FC -11% p=0.068, BG -8%
p=0.16, WM -9% p=0.03). The mean Cr concentrations in these
untreated SIV-infected animals were elevated in all four regions,
but statistical significance was found only in the parietal cortex and
white matter (PC +14% p=0.01, FC +11% p=0.43, BG +6%
p=0.07 and WM +9% p=0.01).
The initiation of minocycline treatment four weeks after
inoculation in seven animals arrested the decline in NAA and
increase in Cr concentrations in the brains of these animals. The
effect of minocycline treatment and the combined effects of
minocycline with partial immune reconstitution of the CD8 T cell
population are best appreciated when the brain concentrations of
NAA and Cr at the last data point are compared in the three
cohorts. As shown in Figure 4B and C, by 8 wpi NAA
concentrations were lower and Cr concentrations were higher in
every brain region analyzed in the untreated animals when
compared to MN-treated animals. Moreover, the greatest
differences were between the untreated animals and MN-treated
animals that experienced partial recovery of CD8 cells.
Changes in other metabolites. Significant changes in
choline (Cho) were observed in all eleven animals during the
first four weeks of SIV infection (p,0.001), with an increase at 2
wpi followed by a decrease to baseline values or below, as seen in
the WM. In the four SIV-infected, persistently depleted, untreated
animals Cho again increased above baseline levels at 8 wpi (PC
+22%, FC +9%, BG 10%, WM 16%). The increases between 4
and 8 wpi were statistically significant in the PC (p=0.003) and
WM (p=0.003) (data not shown).
In contrast, increases in Cho after 4 wpi were not significant in
MN-treated, short-term CD8-depleted animals. In MN-treated,
persistently CD8-depleted animals, increases in Cho after 4 wpi
were not significant in the parietal cortex; however, Cho did
increase significantly in the WM (p=0.003) and in the BG
(p=0.001). Furthermore, Cho levels in the animals at their last
scan before sacrifice was significantly different among the three
cohorts in the PC and WM (Figure 5) with the lowest Cho levels
observed in the MN-treated, short-term CD8-depleted animals.
Myo-Inositol (MI) levels show an increase at 2 and 4 weeks after
inoculation and then normalization to baseline values (data not
shown). Within the first 4 weeks of infection MI significantly
increased at 2 weeks in the FC and WM (p,0.001 and p=0.027,
respectively) and remained elevated at 4 weeks for all eleven
animals. At later time points, even without treatment, MI
decreases and becomes indistinguishable from baseline levels
(Figure 5). With MN treatment no significant differences in the MI
or MI/Cr trends could be observed.
During the first four weeks of SIV infection, glutamate and
glutamine concentrations (Glx) decreased in the parietal cortex at
2 and 4 wpi compared to baseline values (p=0.002). The same
trends are observed in the other brain regions; however, changes
did not reach statistical significance. After 4 weeks Glx levels did
not change significantly. The Glx levels of the three cohorts at the
animals’ last scan before sacrifice were not significantly different
from each other. Due to the large experimental error and
variance in the measurements of glutamine and glutamate, larger
cohort sizes may be needed to identify any statistically significant
changes.
Neuropathology
Experimental information and histopathology. Table 1
summarizes the experimental information and histopathological
findings for the brains of the animals included in this study. SIV-
infected, persistently depleted, untreated animals euthanized at 8
wpi (n=4) exhibited infiltrates, gliosis, cortical neuronal
degeneration, and satellitosis. One animal had occasional
multinucelated giant cells, the classical hallmark of SIV
encephalitis (SIVE). Additionally, two of the SIV-infected,
untreated animals developed occasional accumulations of
perivascular macrophages consistent with mild SIVE. In total,
three of the four (75%) untreated animals developed infiltrates in
the brain within 8 wpi. In contrast, one of four persistently
depleted MN-treated (25%) and two of three short-term depleted
MN-treated (66%) animals had identifiable infiltrates in the brain
at 8 wpi. Yet, all MN treated animals still exhibited signs of mild to
moderate gliosis. Most MN-treated animals had mild to moderate
neurodegeneration and satellitosis while untreated animals had
moderate to severe neurodegeneration and satellitosis.
Synaptophysin, Microtubule-Associated Protein 2 and
neuronal counts. For all following post-mortem studies a
control cohort of four age-matched uninfected, CD8 T-
lymphocyte depleted animals was introduced to reveal changes
from ‘‘baseline’’. The uninfected CD8-depleted cohort was chosen
Figure 4. Minocycline prevents NAA declines and Cr elevation. (A) NAA/Cr at the last MR scan is significantly different among the three
cohorts in all four brain regions by ANOVA (PC p=0.034, FC p=0.009, BG p=0.024 and WM p=0.0065). NAA/Cr was found to be significantly higher
in MN-treated, persistently CD8-depleted animals compared to animals not treated with MN in the FC (p=0.024), BG (p=0.033) and WM (p=0.029)
by Least Square means t-tests. NAA/Cr was also significantly higher in all brain regions in MN treated, short-term CD8-depleted animals when
compared to the untreated animals (PC p=0.0057, FC p=0.0035, BG p=0.01, and WM p=0.002). No significant differences between the two MN-
treated cohorts were identified. (B) NAA concentrations at the last MR scan are higher in MN-treated animals than in untreated animals. NAA levels
are significantly different among the three cohorts in the BG by ANOVA (p=0.0062). NAA was found to be significantly higher in MN-treated, long-
term CD8-depleted animals (p=0.015) and MN treated, short-term CD8-depleted animals (p=0.0024). No significant differences between the two
MN-treated cohorts were identified. (C) Cr concentrations at the last MR scan are lower in MN-treated animals and are significantly different between
each of the three cohorts in the WM by ANOVA (p=0.0042). Cr was found to be significantly lower in MN-treated, short-term CD8-depleted animals
(p=0.0014) compared to untreated animals. Here, differences between the two MN treated cohorts were also identified (p=0.0092) showing higher
Cr level in long-term CD8-depleted animals. Horizontal bars within boxes represent mean values; height of each box corresponds to a factor of
1.5 times standard deviation. * indicates a significant difference (p#0.05) between groups.
doi:10.1371/journal.pone.0010523.g004
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CD8 depletion. Using in vivo MR spectroscopy and post-mortem
IHC, our group has previously shown that CD8 depletion without
SIV infection does not change brain metabolism or provoke
neuronal or glial degradation [20].
Decreases in the expression of synaptophysin (SYN), an integral
protein in presynaptic terminals, and microtubule-associated protein
2 (MAP2), a marker for neuronal cell bodies and dendrites, reflect
neurodegeneration severity and have been found to correlate to the
degree of neurocognitive impairment in persons with HIV [26].
These neuronal markers were measured using immunohistochemis-
tr yasw ella sneu r on alco u nts ,a ndt here s u l tsar ed i s p la y edi nF i gu r e6
(A, B and C). All three measures of neuronal integrity were lower in
the frontal and parietal cortices in SIV-infected, CD8+ cell-depleted
animals when compared to uninfected CD8+ cell-depleted control
animals. Measurements of these markers in the frontal and parietal
lobes of macaques treated with oral MN starting at 4 wpi revealed
levels of SYN, MAP2 and neuronal counts that were not significantly
different from uninfected CD8-depleted controls.
There was a statistically significant difference in frontal cortex
SYN levels among the four cohorts (ANOVA p=0.04, Figure 6A).
Synaptophysin was higher in MN-treated short-term depleted
animals compared to the untreated cohort. Furthermore, parietal
cortex SYN levels were significantly different among the four
cohorts (ANOVA p=0.04). In the PC SYN levels were higher in
MN-treated persistently depleted animals compared to the
untreated animals, but the difference did not reach significance.
MAP2 levels showed a trend towards significance in the frontal
cortex among the four cohorts (ANOVA p=0.09, Figure 6B) with
increased MAP2 levels in MN-treated, short-term depleted
animals compared untreated animals. Parietal cortex MAP2 levels
were higher in controls and MN-treated animals compared to
untreated animals; however, these differences failed to reach
statistical significance (ANOVA p=0.63).
While a higher number of neurons was observed in the frontal
cortex of uninfected animals and MN-treated animals compared to
the untreated cohort, these differences were not statisticallysignificant
(ANOVA p=0.27). There was, however, a statistically significant
difference in parietal cortex neuronal counts among the four cohorts
Figure 5. Minocycline reduces elevation of choline, not myo-
Inositol. Choline concentrations (left) and myo-Inositol concentrations
(right) in the PC and WM at the time of the last MRI scan comparing the
three cohorts. Cho concentrations are significantly different among the
three cohorts in the PC (p=0.033) and WM (p=0.035) by ANOVA. Cho
levels are significantly lower in MN-treated, short-term CD8-depleted
animals (PC p=0.01 and WM p=0.012) compared to untreated animals.
Differences in MI concentrations at the last MR scan were not
statistically significant among the three cohorts by ANOVA. Horizontal
bars within boxes represent mean values; height of each box
corresponds to a factor of 1.5 times standard deviation. * indicates a
significant difference (p#0.05) between groups.
doi:10.1371/journal.pone.0010523.g005
Table 1. Summary of clinical information and CNS histopathology based on H&E.
Animal
CD8 T Cell
Depletion Treatment
Survival
(days) AIDS
Encephalitis
(infiltrates) Gliosis Satellitosis
Neuro-
degeneration
M5207 Persistent None 57 SIV-related Y (mild) moderate severe severe
M5407 Persistent None 57 Y Y (mild) moderate moderate moderate
M7207 Persistent None 62 Y N mild moderate moderate
M1308 Persistent None 62 Y Y (moderate *) mild severe severe
M7307 Persistent MN 62 SIV-related Y (moderate) moderate moderate moderate
M1508 Persistent MN 60 N N mild moderate moderate
M1608 Persistent MN 60 N N mild mild mild
M3408 Persistent MN 55 Y N mild moderate moderate
M7407 Partial Recovery MN 61 SIV-related Y (mild) mild mild mild
M7507 Partial Recovery MN 62 SIV-related N mild moderate moderate
M1408 Partial Recovery MN 62 N Y (mild) moderate moderate moderate
MNGCs: multinucleated giant cells. * rare MNGCs.
Objective scoring: Five regions within the H&E section of frontal cortex were examined and scored at 106magnification using the following criteria for encephalitis,
satellitosis, and neurodegeneration. Gliosis scoring was performed on 5–8 H&E brain sections.
Encephalitis scoring: Mild- perivascular infiltrated in one brain region; Moderate- perivascular infiltrates in two or more regions plus rare MNGCs; Severe-perivascular
infiltrates in all regions and frequent MNGCs.
Gliosis scoring: Mild- increased cellularity in white matter in one brain region; Moderate- increased cellularity in white matter in two or three regions plus occasional
microglial nodules; Severe- increased cellularity in white matter in all regions with frequent microglial nodules.
Satellitosis scoring: Neurons surrounded by 3 or more glial cells are characterized as mild (occasionally occurring); moderate (frequently) and severe (numerous, in
addition to clusters of 3 or more glial cells at sites of neuronal drop-out).
Neurodegeneration scoring: Mild- occasional angular, shrunken neurons; Moderate- frequent angular, shrunken neurons; Severe- numerous angular, shrunken neurons
and neuronal drop-out.
doi:10.1371/journal.pone.0010523.t001
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untreated animals compared to both the MN-treated persistently
CD8-depleted animals and short-term CD8-depleted animals.
GFAP – marker of astrogliosis. Glial fibrillary acidic
protein (GFAP) is the principal intermediate filament in mature
astrocytes. Astrocytes rapidly synthesize GFAP in response to a
neurologic insult, and it is the most commonly used marker of
astrogliosis. GFAP levels were quantified in the frontal and parietal
cortex of the same four cohorts of animals used for the neuronal
marker determinations described in the previous section
(Figure 6D, ANOVA p=0.05 and ANOVA p=0.0062,
respectively). GFAP was significantly elevated in the frontal and
parietal cortices of the SIV-infected, CD8+ cell-depleted animals
when compared to the uninfected, CD8-depleted control animals
and the two cohorts that were treated with MN. No statistical
difference between the uninfected, CD8-depleted controls and
either of the two MN-treated cohorts was observed.
IBA-1 – marker of microglial activation. Calcium binding
adaptor protein 1, IBA-1 is expressed by resting microglia and is
upregulated when these cells are activated [27]. Widespread
Figure 6. Minocycline preserves neuronal integrity and decreases astrogliosis. Synaptophysin (SYN), Microtubule-associated protein 2
(MAP2), neuronal counts, and glial fibrillary acetic protein (GFAP) levels were quantified in the frontal and parietal cortices of 1) four uninfected CD8-
depleted control animals, 2) four SIV-infected, persistently CD8-depleted untreated animals, 3) four MN-treated, SIV-infected, persistently CD8-
depleted animals and 4) three MN-treated, SIV-infected, short-term CD8-depleted animals. Horizontal bars within boxes represent mean values;
height of each box corresponds to a factor of 1.5 times standard deviation. * indicates a significant difference (p#0.05) between groups. (A)
Frontal cortex SYN levels were decreased in SIV-infected CD8-depleted untreated animals versus uninfected CD8-depleted controls (p=0.007).
Synaptophysin was higher in MN-treated short-term depleted animals compared to untreated animals (p=0.05). No statistical differences between
controls and either of the two MN-treated cohorts were observed. Parietal cortex SYN levels were also decreased in SIV-infected CD8-depleted
untreated animals versus controls (p=0.006). (B) MAP2 levels were decreased in SIV-infected CD8-depleted untreated animals versus controls
(p=0.046) and versus MN-treated, short-term CD8-depleted animals (p=0.02). Parietal cortex MAP2 levels were higher in controls and MN-treated
animals compared to untreated animals; however, these differences fail to yield statistical significance. (C) In the parietal cortex SIV-infected
untreated animals had lower neuronal counts compared to controls (p=0.031). There were decreased numbers of neurons in untreated animals
compared to both the MN-treated persistently CD8-depleted animals (p=0.005) and short-term CD8-depleted animals (p=0.006). (D) Frontal cortex
GFAP levels were increased in the SIV-infected, CD8-depleted untreated cohort compared to uninfected CD8-depleted controls (p=0.023). GFAP
levels in both MN-treated persistently CD8-depleted animals (p=0.023) and short-term CD8-depleted animals (p=0.027) were significantly decreased
compared to the untreated cohort. Increases in parietal cortex GFAP levels were identified in the SIV-infected, CD8-depleted untreated cohort
compared to uninfected controls (p=0.002). GFAP levels in both MN-treated persistently CD8-depleted animals (p=0.0041) and short-term CD8-
depleted animals (p=0.0026) were significantly decreased compared to the untreated cohort.
doi:10.1371/journal.pone.0010523.g006
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was observed at 8 wpi in brains of the animals that were
persistently CD8-depleted (Figure 7A) compared to uninfected,
CD8-depleted control animals. There was substantially less IBA-1
expression in brains of animals from both MN-treated cohorts
indicating reduced microglial activation.
To quantify the degree of IBA-1 upregulation induced by SIV
infection in CD8-depleted animals, immunohistochemistry com-
puter image analysis was performed on brain sections from
uninfected, CD8-depleted control animals along with those from
the two SIV-infected, persistently CD8-depleted cohorts, of which
included one cohort that was MN-treated and one untreated
cohort. We did not perform computer-aided image analyses on
IBA-1 for the three MN-treated, short-term depleted animals and
we recognize that this was an experimental flaw in our study.
Figure 7B shows the IHC image analysis for IBA-1 of brain tissue
sections from the frontal cortex of 1) the uninfected, CD8-depleted
control cohort, 2) the SIV-infected, untreated, CD8-depleted
cohort and 3) the four SIV-infected, MN-treated, persistently
CD8-depleted animals. There was a statistically significant
difference in frontal cortex IBA-1 levels among the three cohorts
(p=0.012). There were more IBA-1 positive particles/mm
2 in the
SIV-infected, untreated, CD8-depleted cohorts compared to the
uninfected, CD8-depleted controls (p=0.004) while there was no
statistically significant difference in IBA-1 positive particles/mm
2
in MN-treated animals compared to the controls. In the parietal
cortex, no significant differences in IBA-1 levels among the cohorts
were observed.
Discussion
HIV-associated neurocognitive disorders continue to be a
significant problem despite the use of highly active anti-retroviral
drugs (HAART), and this has motivated a search for adjunctive
therapies. The SIV-infected accelerated macaque model of
neuroAIDS in combination with in vivo
1H MR spectroscopy
provides an exceptional opportunity to efficiently explore drug
therapies that can control neuronal injury [19]. Using this model
oral minocycline was found to be neuroprotective, detected by
stable levels of N-acetylaspartate, and to reverse increased high
energy metabolism reflected by increased Cr, most likely related to
glial activation. Clues into the mechanism(s) responsible for
neuroprotection include the reversal of astrogliosis, reduction of
microglial activation, and reductions of CSF and plasma viral
loads. HIV-related neurological disease appears to be initiated by
the trafficking of infected monoctyes into the brain [28,29]. Once
in the brain, infected macrophages and microglia initiate a cascade
of events that include release of viral proteins, cytokines and
chemokines [30,31]. This is accompanied by significant astroglial
and microglial activation [32,33]. With disease progression, there
is continued influx of inflammatory cells and ultimately the
formation of productive multinucleated giant cells. During these
events, several neurotoxic substances are released leading to
neuronal injury and death, together which characterize the
biological substrate of the neurocognitive disorders in question.
The SIV-infected rhesus macaque shares very similar pathology
with HIV-infected human patients, including the development of
AIDS, disease of the CNS, and cognitive or behavioral deficits
[34–38]. However, because of its parallels with HIV pathogenesis,
the traditional SIV macaque model is hindered by the low rate of
development of SIVE along with the relatively long latent period
of the virus. In addition, only 25–30 percent of infected macaques
develop encephalitis [34,39]. These factors conspire to make the
testing of potential drug therapies extremely challenging. Thus,
attention has focused on two rapidly progressing SIV/macaque
models. One employs pig-tailed macaques (Macaca nemestrina)
that are co-inoculated with immunosuppressive virus (SIV/
DeltaB670) and a neurovirulent molecularly cloned virus (SIV/
Figure 7. Minocycline reduces microglial activation, assessed
by ionized calcium binding adaptor molecule 1 (IBA-1)
expression. (A) IBA-1 expression in four representative sections from
each of an uninfected, CD8-depleted animal (control), an untreated
SIV-infected CD8-depleted animal (1308), a MN-treated persistently
CD8-depleted animal (7307) and a MN-treated short-term CD8-
depleted animal (7407). Visual inspection reveals less IBA-1 expression
in the MN-treated animals. (B) Immunohistochemistry image analysis
for IBA-1 in brain tissue sections of the frontal cortex. Data is given for
four uninfected, CD8-depleted animals which served as controls
(diamonds), four untreated SIV-infected CD8-depleted animals sacri-
ficed at 8 wpi (solid squares) and four minocycline (MN)-treated
(persistently CD8-depleted) animals. The mean for each cohort is given
as a horizontal black line within its respective box. Upper and lower
boundaries of the boxes correspond to a factor of 1.5 times the
standard deviation. There was a statistically significant difference in
frontal cortex IBA-1 levels among the three cohorts (p=0.012). There
are more IBA-1 positive particles/mm
2 in the SIV-infected, CD8-
depleted, untreated cohort compared to -uninfected, CD8-depleted
controls (p=0.004). There was no statistically significant difference in
IBA-1 positive particles/mm
2 in MN-treated animals compared to the
uninfected CD8-depleted controls.
doi:10.1371/journal.pone.0010523.g007
Neuroprotection by Minocycline
PLoS ONE | www.plosone.org 9 May 2010 | Volume 5 | Issue 5 | e1052317E-Fr) [40–43]. The second model retains the use of the SIV-
infected rhesus macaque, but uses a monoclonal antibody to
deplete the animal of CD8+ lymphocytes to accelerate CNS
disease progression [17–19,44,45]. While the development of SIV-
induced neuronal injury is much more rapid in the accelerated
CD8 depletion model of neuroAIDS compared to that in humans,
the underlying biology leading to neuronal injury appears similar.
The hallmark neuropathological abnormalities observed in
humans are also present in this model including the accumulation
of viral-laden perivascular macrophages, encephalitis, astrogliosis,
microgliosis, and neuronal injury.
Moreover, the neuroimaging abnormalities observed in this
animal model are similar to changes in HIV-infected patients that
correlate with neurocognitive impairment. Chang et al. reported
10% decreases in NAA/Cr in patients with mild cognitive motor
dysfunction [46], while 15–28% decreases in NAA or NAA/Cr
have been reported for those with severe cognitive impairment or
AIDS Dementia Complex [47–50].
Declines in the neuronal marker NAA and in NAA/Cr have
been found to correlate with disease severity of macaque SIV
encephalitis [51–54]. Increased Cr levels have been reported in
antiretroviral-naı ¨ve, HIV-infected patients [55,56] as well as in
macaques shortly after SIV infection [57]. The increase in Cr most
likely reflects increased metabolic demands of activated glia and
inflammatory cells [23,24]. Other changes include elevations in
Cho [58,59,60], which likely reflect increased membrane turnover
occurring during glial activation and inflammation [50,52,61,62].
Similar metabolic changes were observed in the present study, and
those changes were reversed or arrested by treatment with
minocycline.
Minocycline treatment beginning at 4 wpi was found to arrest
further decrease in NAA/Cr in SIV-infected, persistently CD8 T
cell depleted animals. In addition, a complete recovery of NAA/
Cr was observed in MN-treated animals that had partial immune
reconstitution of the CD8 T cell population. The recovery of the
NAA/Cr ratio was found to be due to increases in NAA,
suggesting neuronal recovery, and decreases in Cr, possibly
reflecting downregulation of glial and inflammatory cell activation.
These salutary effects observed by brain imaging were accompa-
nied by clinical improvement including weight gain (data not
shown).
The beneficial effects of MN on neuronal health were confirmed
by post-mortem analyses. Synaptophysin (SYN) is a membrane-
bound glycoprotein of the small synaptic vesicles, consistently
expressed in all pre-synaptic nerve endings of the CNS [63].
MAP2 is a high-molecular-weight protein that localizes to the
dendritic compartment of neurons and is involved in microtubule
assembly. Both SYN and MAP2 have been shown to be very
useful in measuring the degree neuronal damage occurring due to
neuroAIDS [64]. Untreated SIV-infected, CD8+ cell-depleted
animals demonstrated markedly decreased expression of SYN and
MAP2 compared with uninfected controls, while MN-treated
animals did not differ from uninfected controls. Furthermore,
minocycline treatment resulted in increased neuronal counts
compared to untreated SIV-infected animals.
Minocycline has been found to be neuroprotective in models of
several neurological diseases including ischemia [65,66], multiple
sclerosis [67], Parkinson’s disease [68], Huntington’s disease [69]
and recently in neuroAIDS [15,16,70,71]. The neuroprotective
properties of MN are thought to be mediated at least partly
through downregulation of microglial activation [11,72,73]. The
possible role of this mechanism in the present study is supported by
the finding that MN-treated animals had lower levels of IBA-1
expression, a marker increased with microglial activation,
compared to the untreated cohort. Levels of IBA-1 expression in
the MN-treated animals, however, still remained higher than levels
in uninfected animals. Additionally, GFAP was decreased in MN-
treated animals compared to untreated SIV-infected macaques.
The possibility that four weeks of MN treatment does not fully
reverse glial activation was also supported by the observation of
persistent mild gliosis in treated animals by hematoxylin and eosin
staining. These results suggest that while short-term MN treatment
arrests neuronal injury, longer treatments of MN may be necessary
to fully normalize glial activity.
Another possible mechanism for neuroprotection is suggested by
the finding of lower viral loads in MN-treated, SIV-infected
macaques. Indeed, complete recovery of NAA/Cr was observed in
the animals with partial immune reconstitution of the CD8 T cell
population. These animals had the lowest levels of plasma viral
loads of the three SIV-infected cohorts. A similar effect by MN in
a different nonhuman primate model of accelerated AIDS was
reported by Zink [16]. Lower plasma viral loads could lead to
reduced trafficking of infected cells into the CNS, and this alone
may be sufficient to allow the innate recovery mechanisms in the
brain to overcome continuing effects of residual virus. Evidence
supporting this approach includes the observation of neuronal
injury reversal in this model, which occurred when macaques were
treated with combination anti-retroviral drugs that did not
penetrate the CNS [19]. The mechanism by which minocycline
is able to reduce viral loads has yet to be elucidated. One
possibility is that MN affects immune cells outside the CNS in a
manner similar to microglia in the brain. That is, it may
downregulate immune cells that normally are productively
infected by the virus. Si et al. [15] and Zink et al. [16,70] have
demonstrated that the anti-viral effect of MN reduces viral burden
in microglial cultures and in the brain, respectively. It has been
suggested that the drug’s anti-viral activity is mediated by its
binding to the HIV integrase activity site [71].
All four untreated and four of the seven minocycline-treated
animals had persistent depletion of CD8+ lymphocytes. However,
three of the treated animals had partial recovery of CD8+
lymphocytes. This latter cohort was distinct from the other two
with respect to viral loads, imaging, neuropathology and other
measures. The better profile of this cohort demonstrates the
essential role of CD8+ lymphocyte depletion in producing the
neuroAIDS spectrum up to SIV encephalitis. It also demonstrates
that while MN treatment alone is insufficient to fully protect the
brain in this model and, presumably, the brain in HIV-infected
individuals, a combination of approaches may lead to superior
results. Thus, the best strategy to treat neuroAIDS may be with
combination therapy of minocycline and antiretroviral therapy.
Some studies have found conflicting results with respect to the
neuroprotective properties of minocycline [73–77]. In fact, some
have even reported a harmful effect on patients with amyotrophic
lateral sclerosis [78]. Therefore, it is essential to determine
minocycline’s mechanism of action in preparation for further
clinical trials for neuroAIDS treatment. Furthermore, not all
subjects may respond equally to MN treatment, thus, more studies
to explore genetic or other confounding factors are necessary to
understand differences in therapeutic effects.
In conclusion, short-term administration of oral minocycline
resulted in significant neuroprotection in the SIV-infected
macaque accelerated model of neuroAIDS. The study also
demonstrated the efficacy of in vivo
1H MR spectroscopy to
noninvasively assess minocycline as a neuroprotective agent in
neuroAIDS and suggests that the integration of MR spectroscopy
should be considered for use in clinical trials of minocycline in
patients with HAND.
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Ethics Statement
All animal studies were performed in accordance with federal
laws and regulations, international accreditation standards, and
institutional policies, including approval by the Massachusetts
General Hospital Subcommittee on Research Animal Care and
the Institutional Animal Care and Use Committee of Harvard
University. All animals received environmental enrichment and
were monitored daily for evidence of disease and changes in
attitude, appetite, or behavior suggestive of illness. Appropriate
clinical support was administered under the direction of the
attending veterinarian and included analgesics, antibiotics,
intravenous fluids, and other supportive care. Animals were
euthanized when they presented with advanced stages of AIDS;
criteria for euthanasia included 15% weight loss in two weeks,
unresponsive opportunistic infection, persistent anorexia, intrac-
table diarrhea, progressive neurologic signs, significant cardiac or
pulmonary signs or other serious illness.
Non-human Primates
Eleven 4–5 years old (7 male) rhesus macaques (Macaca
mulatta) were included in this study (Table 1). All animals were
inoculated with SIVmac251 virus (10 ng SIVp27, i.v.) and their
CD8+ T-lymphocytes were depleted with antibody targeted
against CD8 (cM-T807) at 6, 8 and 12 days post inoculation
(dpi). In this prospective study all infected animals were studied
until 8 weeks post inoculation before being euthanized. Seven
animals were treated orally with 4 mg/kg/day minocycline
(2 mg/kg twice a day) starting at 4 wpi. Minocycline powder
was compounded by Birds’ Hill Compounding Pharmacy
(Needham, MA) into cherry flavored syrup, which was further
diluted into sports drinks or juices. The appropriate dose was given
via a syringe to ensure animals consumed the entire doses. All
animals selected for treatment showed high acceptance levels. No
adverse effects or side effects were observed.
Animals were scanned two times before infection and biweekly
until sacrifice. For MR imaging, each animal was tranquilized with
15–20 mg/kg intramuscular ketamine hydrochloride and intubat-
ed to ensure a patent airway during the experiment. Intravenous
injection of 0.4 mg/kg atropine was administered to prevent
bradycardia. Continuous infusion of approximately 0.25 mg/kg/
min propofol was maintained throughout imaging via catheter in a
saphenous vein. Heart rate, oxygen saturation, end-tidal CO2 and
respiratory rate were monitored continuously. A heated water
blanket was used to prevent hypothermia. All animals were
anesthetized with ketamine-HCl and euthanized by intravenous
pentobarbital overdose.
One additional cohort of four uninfected CD8-depleted
macaques (4.6 years old, 4 males) were included for the post-
mortem evaluations as control cohort.
MRI and MRS
All experiments were performed with a 3 Tesla whole-body
imager (Magnetom TIM Trio, Siemens AG, Erlangen, Germany)
using a circularly polarized transmit-receive extremity coil. First, a
three-plane localizer was performed to position the monkey in the
coil. In this manner, voxel placement was highly reproducible. To
image-guide the
1H MRS volume of interest (VOI), sagittal and
axial turbo spin echo MRI were acquired at 1406140 mm
2 field
of view (FOV), TE=16 ms and 5126512 matrix size. Other
imaging parameters include a 2 mm slice thickness for sagittal
images, a 1.2 mm slice thickness for axial images and repetition
times (TR) of 4500 ms and 7430 ms for sagittal and axial images,
respectively.
Single voxel
1H MR spectroscopy was performed in the parietal
cortex (PC), frontal cortex (FC), basal ganglia (BG) and white
matter semiovale (WM) using a point resolved spectroscopy
sequence (PRESS) with water suppression enhanced through T1
effects (WET) [79] using the following parameters: TE=30 ms,
TR=2500 ms and 192 acquisitions.
All spectra were processed offline using the LCModel software
package [80] to determine the quantities of the brain metabolites
N-acetylaspartate and N-acetylaspartylglutamate (collectively re-
ferred to as NAA), choline-containing compounds (referred to as
Cho), myo-inositol (MI), and creatine-containing compounds
(referred to as Cr). Metabolite ratios were calculated with respect
to creatine. Furthermore, metabolite concentrations were estimat-
ed using the unsuppressed water signal from the same voxel, which
served as the internal standard resulting in institutional units
reflecting millimolar concentration.
Viral Loads and Flow Cytometry
Blood and CSF were drawn before every MR scan, blood was
centrifuged, and plasma and CSF were stored at 280uC until
study endpoint. Virion-associated SIV RNA in plasma was
measured by using a real-time reverse transcription-PCR assay
on an Applied Biosystems (Foster City, CA) Prism 7700 sequence
detection system with a threshold sensitivity of 100 copy eq/mL, as
previously described [81]. Results represent mean values of
duplicate determinations.
CD8+ T lymphocyte depletion was monitored by flow
cytometry prior to infection and CD8 depletion and weekly
thereafter. Flow cytometric analyses were performed with 100-ml
aliquots of blood incubated with fluorochrome-conjugated anti-
bodies including anti–CD3-APC (clone FN18; BioSource Inter-
national), anti–CD4-FITC (OKT4; Ortho Diagnostic Systems),
anti–CD8-PE (DK25; DakoCytomation), and anti–CD20–PE–
Texas Red (B1; Beckman Coulter). Following antibody incubation
for 15 minutes at room temperature, cells were washed twice with
PBS containing 2% FBS; erythrocytes were lysed using Immuno-
Prep Reagent System (Beckman Coulter); and samples were
washed with PBS, resuspended in 2% formaldehyde in PBS and
analyzed on a FACSCalibur flow cytometer (BD). The absolute
number of CD8+ T lymphocytes was determined by multiplying
the percentage of CD8+ CD3+ T cells by absolute lymphocyte
counts obtained using a standard veterinary 3-point WBC
differential, CBC Hematology Analyzer (Hema-True, HESKA).
Histology and Immunohistochemistry
At day of sacrifice, all animals were anesthetized with ketamine-
HCl and euthanized by intravenous pentobarbital overdose. Animals
were perfused with 4 liters of chilled saline, and CNS tissues were
collected in 10% neutral buffered formalin, embedded in paraffin,
sectioned at 6 mmand stained with hematoxylin and eosin(H&E). All
H&E sections were evaluated by a neuropathologist.
Microglial activation was assessed by quantifying calcium
binding adaptor protein 1 (IBA-1). Frontal and parietal cortical
brain sections of the four untreated animals euthanized at 8 wpi
and the four persistently CD8-depleted animals were incubated
with rabbit anti-IBA-1 (Wako Corp. Japan) to determine the
amount of microgliosis. In addition, frontal cortex and parietal
cortex from four uninfected, CD8-depleted animals served as the
control cohort for the IBA-1 analyses. Images of tissue sections
were captured without manipulation using an Olympus 3-CCD
T60C color video camera mounted on an Olypus Vanox-SI
microscope and analyzed using NIH Image J software.
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protein (GFAP), synaptophysin (SYN), microtubule-associated
protein 2 (MAP2) and neuronal counts was performed on fifteen
animals: 1) four uninfected CD8-depleted control animals, 2) the
four SIV-infected, CD8-depleted untreated animals sacrificed at 8
wpi, 3) the four MN-treated, persistently CD8-depleted SIV-
infected animals and 4) the three MN-treated, short-term CD8-
depleted, SIV-infected animals.
The degree of reactive astrogliosis was assessed with the
monoclonal anti-glial fibrillary acidic protein (1:1000; Boehringer
Mannheim, Indianapolis, IN). 5 mm-thick paraffin sections from
the frontal cortex were immunolabeled overnight with these
monoclonal antibodies followed by biotinylated horse anti-mouse
immunoglobulin G, avidin-horseradish peroxidase (Vectastain
Elite kit; Vector, Burlingame, CA), and reacted with diamino-
benzidine tetrahydrochloride and peroxide (0.03%). The integrity
of the synapses was evaluated with the monoclonal antibody
against synaptophysin (1:10) (Boehringer Mannheim, Indianapolis,
Ind). The status of neuronal dendrites was evaluated by using
monoclonal antibody against microtubule-associated protein 2
(MAP2) (Boehringer Mannheim).
Levels of GFAP, synaptophysin, and MAP2 were estimated by
means of computer-aided image analysis, as previously described
[82]. Immunoreactivity was semiquantitatively assessed as cor-
rected optical density by using a microdensitometer (Quantimet
570C; Leica, Microsystem Cambridge, UK). For this purpose,
three immunolabeled sections were analyzed from each case. As
previously described [53,61,82], the system was first calibrated
with a set of filters of various densities, and 10 images were
obtained for each section at6100 magnification. After the area of
interest (layers 2–5) was delineated with the cursor, the optical
density within that area was obtained. The optical density in each
image was averaged and expressed as the mean per case. The units
of all measurements for GFAP and synaptophysin are in arbitrary
optical density units and range from 0 to 500 (i.e., 0 indicates all
light is allowed to pass through the sample, while 500 indicates no
light is allowed to pass through the sample). All values are
expressed as mean 6 standard error of the mean. MAP2 is given
in percent area of the neuropil covered by MAP2 immunoreactive
dendrites.
The number of cortical neurons was quantified by using
stereologic evaluation. Formalin-fixed paraffin sections (7 mm
thick) from the frontal and parietal cortex were stained with
cresyl violet for subsequent computer-aided image analysis as
previously described [83]. The volume-weighted neuronal number
density was calculated by dividing neuronal volume fraction by the
mean number-weighted neuronal volume. These estimations were
derived by using an oil immersion objective lens (numerical
aperture, 1.25) at 1006magnification to analyze contiguous fields
of 65665 mm, with four such fields across and down through full
thickness of cortex. Neurons were included only if an in-focus clear
nucleolus and Nissl substance could be identified.
Statistical Methods
For the serial in vivo MR spectroscopy data and viral loads,
repeated measures analysis of variance (RM-ANOVA) in combi-
nation with Holm’s t-tests was employed to isolate differences
between time-points within the cohorts using JMP 7.0 (SAS, Cary,
NC). For the post-mortem measures including IBA-1, SYN, MAP2,
GFAP, neuronal counts and last MRS scans before sacrifice,
ANOVA was performed among the cohorts and if found to be
significant, Least Square Means Student’s t-tests were used to
isolate which cohort was significantly different. A p-value of #
0.05 was considered to be significant.
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